Completed PHASE4 INTERVENTIONAL NCT01064947

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study

Sponsor: Derm Research, PLLC

Conditions Atopic Dermatitis Secondary Infection

Interventions Retapamulin 1%

Updated 7 times since 2017 Last updated: Aug 15, 2016 Started: Feb 28, 2010 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Atopic Dermatitis and Secondary Infection, this trial is completed. The trial is conducted by Derm Research, PLLC and has accumulated 7 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Derm Research, PLLC
GlaxoSmithKline

Data source: Derm Research, PLLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Louisville, United States